|
2024
|
Invention
|
Chimeric antigen receptors with enhanced signaling and activities and uses thereof.
Provided her... |
|
|
Invention
|
Methods for detecting genomic abnormalities in cells.
The instant disclosure relates to methods ... |
|
|
Invention
|
Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells.
The present... |
|
|
Invention
|
Methods of manufacturing allogeneic car t cells.
Described herein are improved media for culturi... |
|
|
Invention
|
Engineered cells. The present disclosure relates generally to nucleic acid constructs containing ... |
|
|
Invention
|
Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof. The present dis... |
|
|
Invention
|
Modified caspase-9 polypeptides and methods of use thereof.
Provided herein are modified caspase... |
|
|
Invention
|
Methods of detection for engineered cells. Provided herein are approaches to detect the expressio... |
|
|
Invention
|
Constitutively active chimeric cytokine receptors.
Provided herein are constitutively active chi... |
|
|
Invention
|
Inhibitory chimeric antigen receptors.
The invention relates to an inhibitory chimeric antigen r... |
|
2023
|
Invention
|
Rituximab-resistant chimeric antigen receptors and uses thereof.
Provided herein are polynucleot... |
|
|
Invention
|
Cd70 anti-idiotype antibodies.
Provided herein are anti-idiotype antibodies that specifically re... |
|
|
Invention
|
Cd70 anti-idiotype antibodies. Provided herein are anti-idiotype antibodies that specifically rec... |
|
|
Invention
|
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof.
Provided ... |
|
|
Invention
|
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof. Provided h... |
|
|
Invention
|
Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells. The present ... |
|
|
Invention
|
Mab-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells.
A po... |
|
|
Invention
|
B-cell maturation antigen (bcma) anti-idiotypic antibodies.
Provided herein are anti-idiotype an... |
|
|
Invention
|
B-cell maturation antigen (bcma) anti-idiotypic antibodies. Provided herein are anti-idiotype ant... |
|
|
Invention
|
Method for inhibiting adventitious viral infection.
The instant disclosure relates to methods fo... |
|
|
Invention
|
In vitro method for inhibiting hhv-6 infection. The instant disclosure relates to methods for pre... |
|
|
Invention
|
Chimeric cytokine receptors bearing a pd-1 ectodomain.
Provided herein are PD-1 chimeric cytokin... |
|
|
Invention
|
Engineered cells with reduced gene expression to mitigate immune cell recognition.
Provided here... |
|
|
Invention
|
Engineered cells with reduced gene expression to mitigate immune cell recognition. e.g.e.g.e.g., ... |
|
|
Invention
|
Anti-talen antibodies and uses thereof.
The present disclosure provides, among other things, ant... |
|
|
Invention
|
Methods for detecting genomic abnormalities in cells. The instant disclosure relates to methods f... |
|
|
G/S
|
Pharmaceutical preparations, namely, preparations for use in
the treatment of cancer and tumors;... |
|
|
G/S
|
Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors; ... |
|
|
Invention
|
Methods for donor cell analysis.
Provided herein are methods, kits and reagents for analyzing th... |
|
|
Invention
|
Methods for donor cell analysis. Provided herein are methods, kits and reagents for analyzing the... |
|
|
Invention
|
Dll3 targeting chimeric antigen receptors and binding agents.
Provided herein are DLL3 binding a... |
|
|
Invention
|
Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signal... |
|
|
G/S
|
Promoting public awareness about cancer; promoting public awareness about chimeric antigen recept... |
|
|
G/S
|
Printed publications, namely, pamphlets and brochures about
research, detection, diagnosis, and ... |
|
2022
|
Invention
|
Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence... |
|
|
Invention
|
Modified caspase-9 polypeptides and methods of use thereof. Provided herein are modified caspase-... |
|
|
Invention
|
Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and... |
|
|
Invention
|
Formulations and processes for car t cell drug products. Provided herein are formulations and dru... |
|
|
Invention
|
Methods for transducing immune cells. Provided herein are improved methods for transducing immune... |
|
|
Invention
|
Knockdown or knockout of one or more of tap2, nlrc5, b2m, trac, rfx5, rfxap and rfxank to mitigat... |
|
|
Invention
|
Knockdown or knockout of one or more of tap2, nlrc5, β2m, trac, rfx5, rfxap and rfxank to mitigat... |
|
2021
|
Invention
|
Protease-activating cd45-gate car. A reversibly gated effector polypeptide e.g. a chimeric antige... |
|
|
Invention
|
Methods and reagents for characterizing car t cells for therapies. Provided herein are methods, k... |
|
|
Invention
|
Methods and reagents for characterizing car t cells for therapies.
Provided herein are methods, ... |
|
|
Invention
|
Chimeric antigen receptors with enhanced signaling and activities and uses thereof. Provided here... |
|
|
Invention
|
Combination therapies of chimeric antigen receptors targeting b-cell maturation antigen and gamma... |
|
2019
|
G/S
|
Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumours;... |
|
2018
|
G/S
|
Providing medical information to patients and medical professionals in the form of reports in the... |
